On September 1, 2020, the Food and Drug Administration approved azacitidine tablets (ONUREG®, Celgene Corporation) for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
On Monday, August 23, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, and Stand Up To Cancer (SU2C) Health Equity Committee Chair Edith Perez, MD, met virtually to discuss the importance of health equity and the work ASCO and Stand Up To Cancer are doing to increase diversity in cancer research and treatment.
On September 17, the American Society of Clinical Oncology (ASCO) will host ASCO Practice Leadership: E&M Codes For 2021. During this free webinar, Allison Hirschorn, Senior Coding and Reimbursement Specialist, Clinical Affairs at ASCO, will review new information and changes regarding the office and outpatient Evaluation and Management (E&M) services Current Procedural Terminology (CPT ®) codes (99202-99215), which go into effect January 1, 2021.
On September 16, the Association for Clinical Oncology (ASCO) will be hosting its first ever completely virtual Advocacy Summit. Oncology care providers from across the United States will meet with Members of Congress and their staff by phone or video to advocate for policies that will improve access to high-quality, equitable care for people with cancer and ensure robust funding for cancer research.
The American Society of Clinical Oncology (ASCO) released its 2020 Workforce Information Systems (WIS) report, which assembles the latest available data on oncologist supply and demand in the United States to provide a close look at a critical segment of the workforce who care for people with cancer.
On August 25, 2020, the Centers for Medicare & Medicaid Services (CMS) released its third COVID-19-related interim final rule with comment period (IFC). Provisions from the rule impact hospital and laboratory COVID-19 reporting, as well as testing for Medicare beneficiaries. Comments are due 60 days after publication in the Federal Register.
The Association for Clinical Oncology (ASCO) recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the Medicare and Medicaid Programs; CY 2021 Home Health Prospective Payment System Rate Update; Home Health Quality Reporting Requirements; and Home Infusion Therapy Services Requirements (CMS-1730-P) proposed rule.
The Association for Clinical Oncology (ASCO) recently submitted comments to the Office of the National Coordinator for Health Information Technology (ONC) in response to its request for comments on improving patient identification and matching in the nation’s health information technology infrastructure.
On August 20, 2020, the Food and Drug Administration approved carfilzomib (KYPROLIS, Onyx Pharmaceuticals, Inc.) and daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
Reducing the risk for skin cancer requires targeted strategies in four areas, a policy statement from the American Society of Clinical Oncology reports. The statement, published online in May and in the August print edition of JCO Oncology Practice, makes recommendations on the prevention of the three most prominent skin cancers, melanoma, basal cell carcinoma, and squamous cell carcinoma, across four core areas: indoor tanning, sun-protection promotion, community education and outreach, and the role of the oncology provider.
American Society of Clinical Oncology (ASCO) President Lori J. Pierce, MD, FASTRO, FASCO, and American Cancer Society Cancer Action Network (ACS CAN) President Lisa A. Lacasse, MBA, contributed an editorial for Urban One’s Engaging Black America issue, where they discuss the need to prioritize policy solutions that address systemic health disparities.
The Association for Clinical Oncology (ASCO) today released a statement applauding the implementation of the Research to Accelerate Cures and Equity (RACE) for Children Act. As of today, applications to the Food and Drug Administration for marketing approval of new drugs and biological products—including orphan drugs that have relevance to pediatric cancer—must include an assessment of pediatric use.
Qualifying members of the American Society of Clinical Oncology (ASCO) can access Personal Protective Equipment (PPE) through Project N95, a not-for-profit organization, that is providing an opportunity for members who are having difficulty obtaining PPE for their patients and staff during the COVID-19 pandemic.
The American Society of Clinical Oncology (ASCO) invites you to help shape a new initiative to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer. As part of the ASCO and the Association of the Community Cancer Centers (ACCC) recently announced collaboration, ASCO is seeking novel strategies and practical solutions to increase participation of under-represented racial and ethnic populations in cancer treatment trials. The ASCO-ACCC Request for Ideas closes August 24, and submissions are being accepted online.
The U.S. Department of Health and Human Services (HHS) announced it is reopening the application portal for Provider Relief Funds (PRF) to two groups of Medicare providers: providers who missed the opportunity to apply for additional funding from the Phase 1 Medicare General Distribution and providers who had a change in ownership.